You are here:

Forthcoming Submission: crizotinib (Xalkori)

Indication: First line treatment of adults with anaplastic lymphoma kinase positive advanced non small cell lung cancer.

Drug Details

Drug Name: crizotinib (Xalkori)
Drug Manufacturer: Pfizer Ltd
BNF Category:
Sub Category: 8.1 Cytotoxic drugs
Submission type: Full submission
Patient Interest Group
Submission Deadline:
4/04/2016
SMC Meeting Date: 7/06/2016
Advice Due: 11/07/2016

Back